Cargando…

Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials

Cell therapy involves transplantation of human cells to promote repair of diseased or injured tissues and/or cells. Only a limited number of mostly small‐scale trials have studied cell therapy in nonischemic cardiomyopathy (NICM). We performed a meta‐analysis of randomized clinical trials (RCTs) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Avnish, Khan, Mohammad Saud, Khan, Abdur Rahman, Vaughn, Vida M., Bolli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459637/
https://www.ncbi.nlm.nih.gov/pubmed/34346555
http://dx.doi.org/10.1002/sctm.21-0094
_version_ 1784571568791224320
author Tripathi, Avnish
Khan, Mohammad Saud
Khan, Abdur Rahman
Vaughn, Vida M.
Bolli, Roberto
author_facet Tripathi, Avnish
Khan, Mohammad Saud
Khan, Abdur Rahman
Vaughn, Vida M.
Bolli, Roberto
author_sort Tripathi, Avnish
collection PubMed
description Cell therapy involves transplantation of human cells to promote repair of diseased or injured tissues and/or cells. Only a limited number of mostly small‐scale trials have studied cell therapy in nonischemic cardiomyopathy (NICM). We performed a meta‐analysis of randomized clinical trials (RCTs) to assess the safety and efficacy of cell therapy in NICM. Electronic databases were searched for relevant RCTs from inception until August 2020. Outcomes assessed were left ventricular ejection fraction (LVEF), left ventricular end‐diastolic diameter or volume (LVEDD), quality of life (QoL) indices, and major adverse cardiac events (MACEs). Weighted mean differences (MDs) and standardized mean differences (SMDs) were calculated using random‐effects methods. Eleven RCTs with 574 participants were included in the analysis. There was a significant increase in mean LVEF (MD, 4.17%; 95% confidence interval [CI] = 1.66‐6.69) and modest decrease in LVEDD (SMD, −0.50; 95% CI = −0.95 to −0.06) in patients treated with cell therapy compared with controls. Cell therapy was also associated with improvement in functional capacity, as assessed by the 6‐minute walking distance (MD, 72.49 m; 95% CI = 3.44‐141.53). No significant differences were seen in MACEs and QoL indices between treated and control groups. This meta‐analysis suggests that cell therapy may improve LV systolic function and may be associated with improvement in LVEDD and functional capacity compared with maximal medical therapy. Cell therapy was safe, with no significant difference in MACEs between treatment and control groups. However, given the limitations of current studies, larger well‐designed RCTs are needed to evaluate the efficacy of cell therapy in patients with NICM.
format Online
Article
Text
id pubmed-8459637
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84596372021-09-28 Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials Tripathi, Avnish Khan, Mohammad Saud Khan, Abdur Rahman Vaughn, Vida M. Bolli, Roberto Stem Cells Transl Med Enabling Technologies for Cell‐based Clinical Translation Cell therapy involves transplantation of human cells to promote repair of diseased or injured tissues and/or cells. Only a limited number of mostly small‐scale trials have studied cell therapy in nonischemic cardiomyopathy (NICM). We performed a meta‐analysis of randomized clinical trials (RCTs) to assess the safety and efficacy of cell therapy in NICM. Electronic databases were searched for relevant RCTs from inception until August 2020. Outcomes assessed were left ventricular ejection fraction (LVEF), left ventricular end‐diastolic diameter or volume (LVEDD), quality of life (QoL) indices, and major adverse cardiac events (MACEs). Weighted mean differences (MDs) and standardized mean differences (SMDs) were calculated using random‐effects methods. Eleven RCTs with 574 participants were included in the analysis. There was a significant increase in mean LVEF (MD, 4.17%; 95% confidence interval [CI] = 1.66‐6.69) and modest decrease in LVEDD (SMD, −0.50; 95% CI = −0.95 to −0.06) in patients treated with cell therapy compared with controls. Cell therapy was also associated with improvement in functional capacity, as assessed by the 6‐minute walking distance (MD, 72.49 m; 95% CI = 3.44‐141.53). No significant differences were seen in MACEs and QoL indices between treated and control groups. This meta‐analysis suggests that cell therapy may improve LV systolic function and may be associated with improvement in LVEDD and functional capacity compared with maximal medical therapy. Cell therapy was safe, with no significant difference in MACEs between treatment and control groups. However, given the limitations of current studies, larger well‐designed RCTs are needed to evaluate the efficacy of cell therapy in patients with NICM. John Wiley & Sons, Inc. 2021-08-04 /pmc/articles/PMC8459637/ /pubmed/34346555 http://dx.doi.org/10.1002/sctm.21-0094 Text en © 2021 The Authors. stem cells translational medicine published by Wiley Periodicals LLC on behalf of AlphaMed Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Enabling Technologies for Cell‐based Clinical Translation
Tripathi, Avnish
Khan, Mohammad Saud
Khan, Abdur Rahman
Vaughn, Vida M.
Bolli, Roberto
Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title_full Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title_fullStr Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title_full_unstemmed Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title_short Cell therapy for nonischemic dilated cardiomyopathy: A systematic review and meta‐analysis of randomized controlled trials
title_sort cell therapy for nonischemic dilated cardiomyopathy: a systematic review and meta‐analysis of randomized controlled trials
topic Enabling Technologies for Cell‐based Clinical Translation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459637/
https://www.ncbi.nlm.nih.gov/pubmed/34346555
http://dx.doi.org/10.1002/sctm.21-0094
work_keys_str_mv AT tripathiavnish celltherapyfornonischemicdilatedcardiomyopathyasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT khanmohammadsaud celltherapyfornonischemicdilatedcardiomyopathyasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT khanabdurrahman celltherapyfornonischemicdilatedcardiomyopathyasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT vaughnvidam celltherapyfornonischemicdilatedcardiomyopathyasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT bolliroberto celltherapyfornonischemicdilatedcardiomyopathyasystematicreviewandmetaanalysisofrandomizedcontrolledtrials